Demographic and diagnosis at admission
The study enrolled 145 patients, 48 were assigned to the anticoagulant/antiplatelet therapy (AAPT) group and 97 to the no-therapy (NT) group. The mean age was 55.3 years, with a statistically significant higher value in patients in the AAPT group (64.2 vs. 51.0, p < 0.0001). No differences were observed for the sex between the 2 groups (Table 1).
Table 1
Demography diagnosis at admission of the sample, overall and by therapy status (anticoagulant/antiplatelet - anti-PLT - therapy versus no therapy).
| Overall sample | Anticoagulant- Anti-PLT therapy | No therapy | |
Variables | (N = 145) | (N = 48) | (N = 97) | p * |
Mean age in years (SD) | 55.3 (16.7) | 64.2 (13.3) | 51.0 (16.6) | < 0.001 |
Male gender, % | 42.1 | 41.7 | 42.3 | 0.9 |
Trauma without aSDH, % | 7.6 | 8.3 | 7.2 | 0.8 |
Trauma with aSDH, % | 44.8 | 39.6 | 47.4 | 0.4 |
Diagnosis at baseline: | | | | |
Intracerebral haemorrhage, % | 39.3 | 35.4 | 41.2 | 0.5 |
Stroke, % | 25.5 | 37.5 | 19.6 | 0.020 |
Others, % | 35.9 | 27.1 | 40.2 | 0.12 |
| (N = 70) | (N = 16) | (N = 54) | |
Median post-operative ICP in mmHg (IQR) | 13.0 (8.0–18.0) | 10.0 (7.0–14.0) | 15.0 (8.0–23.0) | 0.06 |
* Chi-squared test for categorical variables; t-test and Kruskal-Wallis test for parametric and non-parametric continuous variables, respectively. |
SD: standard deviation. IQR: interqurtile range. aSDH: acute subdural hematoma. ICP: intracranial pressure. DVT: deep vein thrombosis. CCI: Charlson Comorbidity Index. GCS: Glasgow Coma Scale. |
A Warfarin, Coumarins; B Rivaroxaban, Dabigatran, Apixaban, ecc. |
Most of the patients in the overall population (44.8%) suffered from a trauma with acute subdural hematoma (aSDH − 39.6% and 47.4% respectively in the AAPT and NT group, p = 0.4).
More than one-third of the patients suffered from intracerebral hemorrhage (39.3%), and a quarter of the patients from an ischemic stroke (25.5%). About 36% of patients had also other diagnoses such as brain contusions, subarachnoid hemorrhage, etc. Only for stroke there was a statistically significant difference: 37.5% vs. 19.6% in the AAPT and NT group respectively; p = 0.020.
Baseline anticoagulant/anti-PLT therapy in the AAPT group
A total of 48 patients were taking anticoagulants or antiplatelets preoperatively. Acetylsalicylic acid (ASA) was the most common used drug (54.2%).
Drug discontinuation was reported in 77.1% of patients with a median time between drug discontinuation and surgery of 1 day.
About one-third (31.0%) of patients in the overall population (27.1% and 33.0% p = 0.5 in the AAPT and NT group respectively) underwent postoperative prophylaxis with heparin for deep venous thrombosis (DVT) prevention. Four patients (8%) restarted ASA with a median time between surgery and drug resumption of 2 days (0–5 days).
No significant differences were found in terms of peri-intraoperative antagonist transfusion between the 2 groups, with platelets as the most common antagonist transfused (Table 2).
Table 2
Baseline anticoagulant/anti-PLT therapy in the AAPT group.
| Overall sample | Anticoagulant- Anti-PLT therapy | No therapy | |
Variables | (N = 145) | (N = 48) | (N = 97) | p * |
Baseline anticoagulant/anti-PLT therapy: | | | | |
Acetylsalicylic acid, % | 17.9 | 54.2 | -- | -- |
Antiplatelets, % | 5.5 | 16.7 | -- | -- |
Vitamin-K antagonist A, % | 3.5 | 10.4 | -- | -- |
Non-VKA Oral Anticoagulants (NOACs), % B | 4.1 | 12.5 | -- | -- |
Antiplatelet + Anticoagulant, % | 4.8 | 12.5 | -- | -- |
Dual antiplatelet, % | 4.1 | 10.4 | -- | -- |
Drug management: | | | | |
Drug discontinuation, % | 27.1 | 77.1 | -- | -- |
Median time between drug discontinuation and surgery, in days (IQR) | -- | 1.0 (0.0–1.0) | -- | -- |
Median time between surgery and drug resumption, in days (IQR) | -- | 2.0 (0.0–5.0) | -- | -- |
Peri-intraoperative antagonists transfusion: | | | | |
Platelet, % | 9.7 | 12.5 | 8.3 | 0.4 |
Fresh frozen plasma, % | 6.2 | 10.4 | 4.1 | 0.14 |
Vitamin K, % | 4.1 | 8.3 | 2.1 | 0.07 |
Post-surgical drugs administration: | | | | |
Heparin for DVT prevention, % | 31.0 | 27.1 | 33.0 | 0.5 |
Acetilsalycilic acid, % | 6.2 | 8.0 | 3.1 | 0.7 |
* Chi-squared test for categorical variables; t-test and Kruskal-Wallis test for parametric and non-parametric continuous variables, respectively. |
SD: standard deviation. IQR: interqurtile range. aSDH: acute subdural hematoma. ICP: intracranial pressure. DVT: deep vein thrombosis. CCI: Charlson Comorbidity Index. GCS: Glasgow Coma Scale. |
Pre-operative risk and clinical scores
Median CHA2DS2-Vasc, HAS-BLED and CCI scores showed statistically significant differences between the 2 groups (p < 0.001) with higher scores in the AAPT group (Table 3).
Table 3
Pre-operative risk and clinical scores.
|
Overall
sample
|
Anticoagulant-
Anti-PLT therapy
|
No therapy
|
|
Variables
|
(N = 145)
|
(N = 48)
|
(N = 97)
|
p *
|
Median CHA2DS2-VASc score (IQR)
|
2.0 (0.0–4.0)
|
4.0 (3.0–5.0)
|
1.0 (0.0–2.0)
|
< 0.001
|
Median HAS-BLED score (IQR)
|
1.0 (0.0–3.0)
|
3.0 (2.0–4.0)
|
1.0 (0.0–1.0)
|
< 0.001
|
Median CCI (IQR)
|
2.0 (1.0–4.0)
|
4.0 (2.0–6.0)
|
2.0 (0.0–3.0)
|
< 0.001
|
Pre-surgical mRS:
|
(N = 131)
|
(N = 40)
|
(N = 91)
|
|
Median score (IQR)
|
4.0 (4.0–5.0)
|
4.0 (3.0–5.0)
|
5.0 (4.0–5.0)
|
0.2
|
Score categories, %
|
|
|
|
0.3
|
0–2 - minor disability
|
16.8
|
17.5
|
16.5
|
|
3–4 - moderate disability
|
33.6
|
42.5
|
29.7
|
|
5 - severe disability
|
49.6
|
40.0
|
53.8
|
|
6 - death
|
0.0
|
0.0
|
0.0
|
|
Pre-surgical GCS:
|
|
|
|
|
Median score (IQR)
|
6.0 (4.0–10.0)
|
6.0 (4.0–10.0)
|
7.0 (4.0–9.0)
|
0.9
|
Score categories, %
|
|
|
|
0.2
|
3–8 - unresponsive
|
70.2
|
64.6
|
73.1
|
|
9–12 - comatose
|
20.6
|
29.2
|
16.1
|
|
13–15 best score
|
9.2
|
6.2
|
10.8
|
|
Coagulation parameters
|
|
|
|
|
Preoperative platelets (median (IQR))
|
212.0(164.0, 269.3)
|
203.0(155.5, 280.7)
|
212.0(164.3, 268.5)
|
0.9
|
Preoperative INR (median (IQR))
|
1.09 (1.04, 1.18)
|
1.11 (1.04, 1.21)
|
1.09 (1.04, 1.15)
|
0.5
|
Postoperative platelets (median (IQR))
|
202.0 (144.0, 270.0)
|
211.0(152.0, 279.0)
|
202.0(141.3, 264.8)
|
0.6
|
Postoperative INR (median (IQR))
|
1.11 (1.05, 1.20)
|
1.12 (1.06, 1.22)
|
1.10 (1.04, 1.19)
|
0.3
|
* Chi-squared test for categorical variables; t-test and Kruskal-Wallis test for parametric and non-parametric continuous variables, respectively. |
SD: standard deviation. IQR: interqurtile range. CCI: Charlson Comorbidity Index. GCS: Glasgow Coma Scale. GOS: Glasgow Outcome Scale. |
Considering the pre-operative mRS and GCS categories, most of the patients presented a score of mRS = 5 (severe disability) (49.6%) and GCS = 3–8 (70.2%), with no statistically significant differences between the groups (p = 0.3 and p = 0.2 respectively) (Table 3).
No statistically significant differences were found between pre- and post-operative platelets count and INR values between the 2 groups.
Post-operative complications and clinical outcome
Post operative acute hemorrhage in the surgical field (24 hours) was reported in 14.1% of patients (20.0 vs 11.3 in the AAPT and NT group respectively, p = 0.2).
New ischemic stroke (not present before treating the patient, and not the cause of the surgery) was reported in 15.3% of patients with a statistically significant difference between the 2 groups (27.7% vs 9.3% in the AAPT and NT group respectively, p < 0.001). Higher incidence of acute myocardial infarction was also significant in the AAPT group (10.6 vs 0.0, p = 0.001).
Median length of stay in the ICU did not show significant differences with a median of 15.0 days (Table 4).
Table 4
Post-operative complications and clinical outcome.
| Overall sample | Anticoagulant- Anti-PLT therapy | No therapy | |
Variables | (N = 145) | (N = 48) | (N = 97) | p * |
Post-surgical outcomes: | | | | |
Haemorrhage, % | 14.1 | 20.0 | 11.3 | 0.2 |
Stroke, % | 15.3 | 27.7 | 9.3 | < 0.001 |
Acute myocardial infarction, % | 3.5 | 10.6 | 0.0 | 0.001 |
Other events, % | 13.9 | 19.2 | 11.3 | 0.2 |
Median post-surgical length of stay in ICU in days (IQR) | 15.0 (7.0–27.0) | 14.0 (9.0–21.0) | 18.0 (6.0–30.0) | 0.2 |
Post-surgical mRS: | (N = 131) | (N = 40) | (N = 91) | |
Median score (IQR) | 4.0 (3.0–5.0) | 5.0 (4.0–5.0) | 4.0 (3.0–5.0) | 0.2 |
Score categories, % | | | | 0.2 |
0–2 - minor disability | 8.4 | 2.5 | 11.0 | |
3–4 - moderate disability | 45.0 | 45.0 | 45.0 | |
5 - severe disability | 46.6 | 52.5 | 44.0 | |
6 - death | 0.0 | 0.0 | 0.0 | |
Post-surgical GCS: | | | | |
Median score (IQR) | 10.0 (5.0–12.0) | 7.5 (3.0–12.0) | 10.0 (5.0–12.0) | 0.08 |
Score categories, % | | | | 0.6 |
3–8 - unresponsive | 46.7 | 52.2 | 44.0 | |
9–12 - comatose | 31.4 | 30.4 | 31.9 | |
13–15 best score | 21.9 | 17.4 | 24.1 | |
Post-surgical GOS: | | | | |
1-month median score (IQR) | 3.0 (2.0–3.0) | 2.5 (1.0–3.0) | 3.0 (2.0–3.0) | 0.06 |
1-month score categories, % | | | | 0.010 |
1- death | 24.5 | 30.4 | 21.5 | |
2–3 - severe disability | 64.0 | 69.6 | 61.3 | |
4–5 - minor disability | 11.5 | 0.0 | 17.2 | |
6-month median score (IQR) | 3.0 (1.0–3.0) | 3.0 (1.0–3.0) | 3.0 (2.0–4.0) | 0.046 |
6-month score categories, % | | | | 0.021 |
1- death | 25.6 | 34.2 | 21.5 | |
2–3 - severe disability | 51.3 | 57.9 | 48.1 | |
4–5 - minor disability | 23.1 | 7.9 | 30.4 | |
* Chi-squared test for categorical variables; t-test and Kruskal-Wallis test for parametric and non-parametric continuous variables, respectively. |
SD: standard deviation. IQR: interqurtile range. CCI: Charlson Comorbidity Index. GCS: Glasgow Coma Scale. GOS: Glasgow Outcome Scale. |
Post operative clinical scores were available for 131 patients, 40 and 91 in the AAPT and NT group respectively.
No differences were found between the 2 groups for post-operative mRS and GCS with most of the patients (91.6%) reported as severe or moderate disability or unresponsive-comatose (78.1%) (Table 4).
One month – post operative GOS categories did show statistically significant differences (p = 0.010) between the 2 groups, with higher risk for death (1) in the AAPT group (30.4% vs 21.5% in AAPT and NT group respectively and for minor disability (4–5) in the NT group (0.0% vs 17.2% in AAPT and NT group respectively). Similar results were found for the 6-month – post operative GOS (Table 4).
Univariate and Multivariate analysis for risk of post-operative hemorrhages
Univariate analysis and multiple logistic regression was performed to analyze the correlation between the preoperative use of antithrombotics or anticoagulants and the development of postoperative hemorrhage (Table 5).
Table 5
Univariate and multivariate analyses evaluating the association between anticoagulant-anti-PLT therapy status and post-surgical onset of hemorrhagic events, adjusting for selected potential confounders.
| Post-surgical hemorrhage (n = 20) |
| Raw OR (95% CI) | p | Adj. OR (95% CI) | p |
Antithrombotic therapy: | | | | |
No | 1 (ref. cat.) | | 1 (ref. cat.) | |
Yes | 1.95 (0.75–5.12) | 0.2 | 2.13 (0.79–5.72) | 0.13 |
Age: | | | | |
5-year increase | 1.06 (0.90–1.23) | 0.4 | -- | -- |
Diagnosis of intracerebral hemorrhage at baseline: | | | | |
No | 1 (ref. cat.) | | 1 (ref. cat.) | |
Yes | 2.66 (1.01-7.0) | 0.048 | 2.82 (1.06–7.53) | 0.04 |
HAS-BLED score : | | | | |
1-point increase | 1.16 (0.86–1.55) | 0.3 | -- | -- |
OR: odds ratio; CI: confidence interval; adj.: adjusted; ref. cat.: reference category. |
The considered variables were: age (at 5-year increase), HAS-BLED, and intracerebral hemorrhage as the cause leading to surgery.
The analysis showed that only intracerebral hemorrhage, as the cause of surgery, independently leads to an increased risk of postoperative hemorrhage in the surgical field (OR 2.82 [1.06–7.53], p = 0.04).
Multivariate analysis for risk of post-operative thromboembolic events
Multiple logistic regression was also performed to analyze the correlation between the use of antiplatelets/anticoagulants before surgery and the development of postoperative thromboembolic events (Table 6).
Table 6
Multivariate analyses evaluating the association between anticoagulant-anti-PLT therapy status and post-surgical onset of thrombotic events, adjusting for selected potential confounders.
| Thrombotic events (n = 38) | |
| % | Adj. OR (95% CI) | p |
Anticoagulant-anti-PLT therapy | | | |
- no | 18.6 | 1 (ref. cat.) | |
- yes | 41.7 | 1.69 (0.58–4.91) | 0.3 |
Age: | | | |
5-year increase | -- | 0.92 (0.78–1.07) | 0.3 |
Diagnosis of ischemia at baseline: | | | |
- no | 18.5 | 1 (ref. cat.) | |
- yes | 48.7 | 3.49 (1.47–8.28) | 0.005 |
CHA2DS2-VASc score: | | | |
− 1-point increase | -- | 1.27 (0.93–1.74) | 0.13 |
OR: odds ratio; CI: confidence interval; adj.: adjusted; ref. cat.: reference category. |
The variables considered were: age (5-year increase), CHA2DS2-Vasc, and ischemic stroke as possible causes leading to the intervention, but only this last one appeared significantly associated with an increased risk of postoperative thromboembolic events (OR 3.49 [1.47–8.28], p = 0.005).
Multivariate analysis for risk of 1 and 6 month – post-operative unfavorable (1–3) GOS
A multiple logistic regression model was performed to analyze the correlation between the use of antiplatelet or anticoagulant medications before surgery and the development of 1 and 6 month – post-operative unfavorable (1–3) GOS (Table 7).
Table 7
Multivariate analyses evaluating the association between anticoagulant-anti-PLT therapy status and (a) 1-month unfavourable GOS, (b) 6-month unfavourable GOS, adjusting for selected potential confounders.
| | 1-month GOS 1–3 | | | 6-month GOS 1–3 | |
| % | Adj. OR (95% CI) | p | % | Adj. OR (95% CI) | p |
Anticoagulant-anti-PLT therapy | | | | | | |
- no | 82.8 | 1 (ref. cat.) | | 69.6 | 1 (ref. cat.) | |
- yes | 100* | -- | -- | 92.1 | 2.10 (0.39–11.3) | 0.4 |
Age: | | | | | | |
5-year increase | -- | 1.14 (0.92–1.42) | 0.2 | -- | 1.08 (0.90–1.29) | 0.4 |
CCI: | | | | | | |
− 1-point increase | -- | 1.20 (0.78–1.85) | 0.4 | -- | 1.11 (0.81–1.52) | 0.5 |
HAS-BLED score: | | | | | | |
− 1-point increase | -- | 1.51 (0.0.57–3.98) | 0.4 | -- | 1.72 (0.85–3.48) | 0.13 |
CHA2DS2-VASc score: | | | | | | |
− 1-point increase | -- | 1.12 (0.54–2.32) | 0.8 | -- | 0.79 (0.49–1.28) | 0.3 |
Pre-surgical GCS: | | | | | | |
− 1-point increase | -- | 0.81 (0.67–0.97) | 0.025 | -- | 0.84 (0.73–0.98) | 0.022 |
OR: odds ratio; CI: confidence interval; adj.: adjusted; ref. cat.: reference category; CCI: Charlson Comorbidity Index. GOS: Glasgow Outcome Scale; GCS: Glasgow Coma Scale. |
* In the model predicting 1-month GOS, the assumption of anticoagulant-anti-PLT therapy perfectly predicts the likelihood of the outcome, thus the covariate was dropped from the model. The raw % shows the proportion of patients with the outcome in each category of exposed and unexposed group (PLT therapy yes vs. no). |
We considered age (5-year increase), CCI (1-point increase), HAS BLED score (1-point increase), CHAD2DS2-VASc score (1-point increase) and pre-surgical GCS (1-point increase) as possible variables associated with outcome, but only the last one showed a statistically significant correlation with a reduced risk for unfavorable GOS at 1 and 6 months OR = 0.81 (CI = 0.67–0.97, p = 0.025).